| Literature DB >> 35890091 |
Mario-Livio Jeličić1, Jelena Kovačić1, Matija Cvetnić2, Ana Mornar1, Daniela Amidžić Klarić1.
Abstract
Since oxidative stress has been linked to several pathological conditions and diseases, drugs with additional antioxidant activity can be beneficial in the treatment of these diseases. Therefore, this study takes a new look at the antioxidant activity of frequently prescribed drugs using the HPLC-DPPH method. The antioxidative activity expressed as the TEAC value of 82 drugs was successfully determined and is discussed in this work. Using the obtained values, the QSAR model was developed to predict the TEAC based on the selected molecular descriptors. The results of QSAR modeling showed that four- and seven-variable models had the best potential for TEAC prediction. Looking at the statistical parameters of each model, the four-variable model was superior to seven-variable. The final model showed good predicting power (r = 0.927) considering the selected descriptors, implying that it can be used as a fast and economically acceptable evaluation of antioxidative activity. The advantage of such model is its ability to predict the antioxidative activity of a drug regardless of its structural diversity or therapeutic classification.Entities:
Keywords: DPPH; HPLC; QSAR prediction; antioxidative activity; pharmaceuticals
Year: 2022 PMID: 35890091 PMCID: PMC9316871 DOI: 10.3390/ph15070791
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Description of investigated pharmaceuticals.
| Name | CAS | Molecular Formula | Pharmacologic Class | ATC * | TEAC (mM) |
|---|---|---|---|---|---|
| Acetazolamide | 59-66-5 | C4H6N4O3S2 | Mitotic | S | 0.009 |
| Amoxicillin | 26787-78-0 | C16H19N3O5S | Antibiotic | J | 0.085 |
| Antipyrine (Phenazone) | 60-80-0 | C11H12N2O | Analgetic | N | 0.013 |
| Atenolol | 29122-68-7 | C14H22N2O3 | Beta blocker | C | 0.037 |
| Atorvastatin | 134523-00-5 | C33H35FN2O5 | Hypolipemic | C | 0.059 |
| Atropine sulphate | 5908-99-6 | C34H50N2O11S | Spasmolytic | A, S | 0.010 |
| Azathioprine | 446-86-6 | C9H7N7O2S | Immunosuppressive | L | 0.001 |
| Azithromycin | 83905-01-5 | C38H72N2O12 | Antibiotic | J | 0.037 |
| Balsalazide | 80573-04-2 | C17H15N3O6 | Aminosalicylate | A | 0.008 |
| Barbital | 57-44-3 | C8H12N2O3 | Sedative | N | 0.001 |
| Benzocaine (4-aminobenzoate) | 94-09-7 | C9H11NO2 | Anaesthetic | N | 0.004 |
| Bisoprolol | 66722-44-9 | C18H31NO4 | Beta blocker | C | 0.008 |
| Caffeine | 58-08-2 | C8H10N4O2 | Analeptic | N | 0.013 |
| Carvedilol | 72956-09-3 | C24H26N2O4 | Beta blocker | C | 0.028 |
| Cefalexin | 15686-71-2 | C16H17N3O4S | Antibiotic | J | 0.170 |
| Cefradine | 38821-53-3 | C16H19N3O4S | Antibiotic | J | 0.152 |
| Chloramphenicol | 56-75-7 | C11H12Cl2N2O5 | Antibiotic | J | 0.041 |
| Cimetidine | 51481-61-9 | C10H16N6S | H2-receptor antagonist | A | 0.018 |
| Ciprofloxacin | 85721-33-1 | C17H18FN3O3 | Antibiotic | J | 0.155 |
| Clarithromycin | 81103-11-9 | C38H69NO13 | Antibiotic | J | 0.044 |
| Codeine phosphate | 41444-62-6 | C18H24NO7P | Analgetic | N | 0.017 |
| Diazepam | 439-14-5 | C16H13ClN2O | Sedative | N | 0.00001 |
| Digoxin | 20830-75-5 | C41H64O14 | Cardiotonic | C | 0.00001 |
| Docetaxel | 148408-66-6 | C43H59NO17 | Cytostatic | L | 0.001 |
| Doxycycline | 564-25-0 | C22H24N2O8 | Antibiotic | J | 0.302 |
| Dopamine | 62-31-7 | C8H12ClNO2 | Dopamine | C | 0.274 |
| Ephedrine | 299-42-3 | C10H15NO | Adrenergic | C | 0.002 |
| Erythromycin | 114-07-8 | C37H67NO13 | Antibiotic | J | 0.080 |
| Febuxostat | 144060-53-7 | C16H16N2O3S | Non-purine xanthine oxidase inhibitor | M | 0.00001 |
| Fluvastatin | 93957-55-2 | C24H25FNNaO4 | Hypolipemic | C | 0.138 |
| Folic acid | 59-30-3 | C19H19N7O6 | Vitamin | A | 0.230 |
| Furosemide | 54-31-9 | C12H11ClN2O5S | Diuretic | C | 0.055 |
| Gemcitabine | 122111-03-9 | C9H12ClF2N3O4 | Cytostatic | L | 0.060 |
| Hydrochlorothiazide | 58-93-5 | C7H8ClN3O4S2 | Diuretic | C | 0.018 |
| Ibuprofen | 15687-27-1 | C13H18O2 | NSAID ** | M | 0.005 |
| Ketoprofen | 22071-15-4 | C16H14O3 | NSAID | M | 0.006 |
| L-Ascorbic acid sodium salt | 134-03-2 | C6H8O6 | Vitamin | A | 0.267 |
| 6-Mercaptopurine | 50-44-2 | C5H4N4S | Immunosuppressive | L | 0.292 |
| Mesalazine | 89-57-6 | C7H7NO3 | Aminosalicylate | A | 0.296 |
| Metronidazole | 443-48-1 | C6H9N3O3 | Antibiotic | J | 0.015 |
| Nebivolol | 99200-09-6 | C22H25F2NO4 | Beta blocker | C | 0.017 |
| Nifedipine | 21829-25-4 | C17H18N2O6 | Calcium channel blocker | C | 0.029 |
| Nicotinamide | 98-92-0 | C6H6N2O | Vitamin | A | 0.048 |
| O-Acetylsalicylic acid | 50-78-2 | C9H8O4 | NSAID | B, N | 0.012 |
| Oxazepam | 604-75-1 | C15H11N2O2Cl | Sedative | M | 0.007 |
| Oxytetracycline | 79-57-2 | C22H24N2O9 | Antibiotic | J | 0.299 |
| Olsalazine | 6054-98-4 | C14H8N2Na2O6 | Aminosalicylate | A | 0.002 |
| Pantoprazole | 102625-70-7 | C16H14F2N3NaO4S | Proton-pump inhibitor | A | 0.030 |
| Calcium pantothenate | 443753 | C18H32CaN2O10 | Vitamin | A | 0.002 |
| Papaverine | 61-25-6 | C20H22ClNO4 | Spasmolytic | A | 0.012 |
| Paracetamol | 103-90-2 | C8H9NO2 | Analgetic | N | 0.236 |
| Phenobarbitone | 50-06-6 | C12H12N2O3 | Sedative | N | 0.038 |
| Physostigmine salicylate | 57-64-7 | C22H27N3O5 | Parasympathomimetic | S | 0.063 |
| Piperazine | 142-63-2 | C4H22N2O6 | Anthelmintic | P | 0.132 |
| Piracetam | 7491-74-9 | C6H10N2O2 | Antidepressant | N | 0.025 |
| Pirfenidone | 53179-13-8 | C12H11NO | Anti-inflammatory, antifibrotic | L | 0.00001 |
| Pravastatin sodium | 81131-70-6 | C23H35NaO7 | Hypolipemic | C | 0.097 |
| Procaine | 51-05-8 | C13H21ClN2O2 | Anaesthetic | N | 0.024 |
| Propyphenazone | 479-92-5 | C14H18N2O | Analgetic | N | 0.003 |
| Propranolol | 525-66-6 | C16H21NO2 | Beta blocker | C | 0.00001 |
| Quetiapine fumarate | 111974-72-2 | C46H54N6O8S | Antipsychotic | N | 0.030 |
| Quinidine | 56-54-2 | C20H24N2O2 | Antiarrhythmic agent | C | 0.029 |
| Quinin sulphate | 207671-44-1 | C40H50N4O8S | Antimalaria | P | 0.017 |
| Rifampicin | 13292-46-1 | C43H58N4O12 | Antibiotic | J | 0.292 |
| Risperidone | 106266-06-2 | C23H27FN4O2 | Antipsychotic | N | 0.010 |
| Ropinirole | 91374-20-8 | C16H25ClN2O | Anti-Parkinson’s drug | N | 0.285 |
| Salicylic acid | 69-72-7 | C7H6O3 | Anti-inflammatory, antibacterial | D | 0.024 |
| Sildenafil citrate | 171599-83-0 | C22H30N6O4S | PDE 5 inhibitor | G | 0.003 |
| Simvastatin | 79902-63-9 | C25H38O5 | Hypolipemic | C | 0.141 |
| Sulfacetamide sodium | 6209-17-2 | C8H11N2NaO4S | Antibiotic | J | 0.015 |
| Sulfadiazine | 68-35-9 | C10H10N4O2S | Antibiotic | J | 0.015 |
| Sulfamethoxazole | 723-46-6 | C10H11N3O3S | Antibiotic | J | 0.077 |
| Sulfasalazine | 599-79-1 | C18H14N4O5S | Aminosalicylate | A | 0.076 |
| Sulfathiazole | 72-14-0 | C9H9N3O2S2 | Antibiotic | J | 0.035 |
| Sulphamic acid | 5329-14-6 | NH2SO3H | Antibiotic | J | 0.104 |
| Sulphanilamide | 63-74-1 | C6H8N2O2S | Antibiotic | J | 0.023 |
| 6-Thioguanine | 154-42-7 | C5H5N5S | Immunosuppressive | L | 0.288 |
| Theobromine | 83-67-0 | C7H8N4O2 | Antiasthmatic | R | 0.011 |
| Theophylline | 58-55-9 | C7H8N4O2 | Antiasthmatic | R | 0.004 |
| Thiamine | 67-03-8 | C12H18Cl2N4OS | Vitamin | A | 0.115 |
| Warfarin | 81-81-2 | C19H16O4 | Anticoagulant | B, N | 0.077 |
| Zopiclone | 43200-80-2 | C17H17ClN6O3 | Sedative | N | 0.018 |
* ATC—Anatomical Therapeutic Chemical Clasification. ** NSAID—Non-steroidal anti-inflammatory drugs.
Selected 1- to 8-variable models for prediction of TEAC on the training set.
| Variable No. | Equation | |
|---|---|---|
| 1 |
| = 0.1739(±0.0687) × C-018 + 0.0500(±0.0156) |
| 2 |
| = 0.1760(±0.0595) × C-018 + 0.1487(±0.0673) × H7s + 0.0287(±0.0166) |
| 3 |
| = 0.1835(±0.0529) × C-018 + 0.1464(±0.0580) × CATS2D_06_AL − 0.1050(±0.0487) × Mor24e + 0.0458(±0.0157) |
| 4 |
| = −0.0851(±0.0533) × Mor16e − 0.1511(±0.0964) × RDF145p + 0.1489(±0.0526) × C-018 + 0.1991(±0.0694) × CATS2D_06_AL + 0.0396(±0.0156) |
| 5 |
| = −0.1657(±0.0819) × RCI − 0.1458(±0.0848) × RDF145p − 0.0847(±0.0469) Mor16e + 0.1484(±0.0463) × C-018 + 0.2113(±0.0613) × CATS2D_06_AL + 0.1292(±0.0463) |
| 6 |
| = −0.1686(±0.0768) × RCI − 0.1695(±0.0811) × RDF145p − 0.0801(±0.0456) × Mor16e + 0.1388(±0.0788) × H7s + 0.1579(±0.0435) × C-018 + 0.1061(±0.0712) × CATS2D_04_AL + 0.1175(±0.0439) |
| 7 |
| = −0.1700(±0.0728) × RCI − 0.1717(±0.0764) × RDF145p − 0.0965(±0.0481) × Mor16u + 0.1412(±0.0745) × H7s + 0.2087(±0.0625) × C-018 + 0.1086(±0.0682) × CATS2D_04_AL − 0.1046(±0.0952) × F03[N-F] + 0.1194(±0.0416) |
| 8 |
| = −0.1880(±0.0673) × RCI − 0.1821(±0.0703) × RDF145p − 0.0861(±0.0442) × Mor16u + 0.0811(±0.0753) × H7s + 0.0606(±0.0386) × nR = Ct + 0.1483(±0.0383) × C-018 + 0.1236(±0.0622) × CATS2D_04_AL + 0.0764(±0.0529) × F06[N-F] + 0.1241(±0.0384) |
Statistical parameters of obtained one- to eight-variable models.
| Model No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
|---|---|---|---|---|---|---|---|---|
| Ntr | 58 | 58 | 58 | 58 | 58 | 58 | 58 | 58 |
| Nex | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
|
| ||||||||
|
| 0.316 | 0.496 | 0.599 | 0.643 | 0.729 | 0.767 | 0.794 | 0.835 |
|
| 0.304 | 0.478 | 0.578 | 0.616 | 0.703 | 0.739 | 0.766 | 0.808 |
|
| 0.0576 | 0.0499 | 0.0499 | 0.0428 | 0.0377 | 0.0353 | 0.0334 | 0.0302 |
|
| 25.885 | 27.109 | 26.986 | 27.846 | 27.974 | 27.977 | 27.629 | 31.059 |
|
| <0.0000 | <0.0000 | <0.0000 | <0.0000 | <0.0000 | <0.0000 | <0.0000 | <0.0000 |
| 0.000 | 0.016 | 0.034 | 0.232 | 0.187 | 0.318 | 0.359 | 0.309 | |
| Δ | 0.562 | 0.337 | 0.238 | 0.154 | 0.135 | 0.073 | 0.053 | 0.060 |
| RMSEtr | 0.056 | 0.49 | 0.043 | 0.041 | 0.036 | 0.033 | 0.031 | 0.028 |
| MAEtr | 0.042 | 0.037 | 0.034 | 0.033 | 0.028 | 0.025 | 0.023 | 0.021 |
| CCCtr | 0.480 | 0.664 | 0.750 | 0.886 | 0.843 | 0.868 | 0.783 | 0.910 |
|
| ||||||||
|
| 0.227 | 0.339 | 0.462 | 0.539 | 0.632 | 0.687 | 0.724 | 0.748 |
| RMSEcv | 0.060 | 0.056 | 0.050 | 0.047 | 0.041 | 0.038 | 0.036 | 0.034 |
| MAEcv | 0.044 | 0.041 | 0.038 | 0.037 | 0.032 | 0.030 | 0.028 | 0.026 |
| PRESScv | 0.210 | 0.180 | 0.146 | 0.126 | 0.100 | 0.085 | 0.075 | 0.068 |
| CCCcv | 0.419 | 0.564 | 0.663 | 0.854 | 0.786 | 0.821 | 0.845 | 0.862 |
|
| ||||||||
| RMSEext | 0.049 | 0.052 | 0.052 | 0.030 | 0.043 | 0.034 | 0.031 | 0.042 |
| MAEext | 0.040 | 0.043 | 0.041 | 0.026 | 0.033 | 0.029 | 0.024 | 0.033 |
| PRESSext | 0.033 | 0.038 | 0.038 | 0.013 | 0.026 | 0.015 | 0.013 | 0.025 |
|
| 0.657 | 0.618 | 0.639 | 0.859 | 0.759 | 0.822 | 0.839 | 0.784 |
|
| 0.606 | 0.544 | 0.551 | 0.845 | 0.687 | 0.809 | 0.840 | 0.707 |
|
| 0.601 | 0.539 | 0.546 | 0.843 | 0.684 | 0.807 | 0.839 | 0.704 |
|
| 0.498 | 0.419 | 0.429 | 0.803 | 0.601 | 0.756 | 0.797 | 0.627 |
| CCCext | 0.703 | 0.784 | 0.792 | 0.913 | 0.777 | 0.883 | 0.907 | 0.805 |
Figure 1Plot showing the obtained r values in relation to variables in the model for the training set (full line) and test set (dashed line).
Correlation matrix of included descriptors in best four- and seven-variable QSAR models predicting TEAC for the entire set of compounds (72).
|
| |||||||
| Mor16e | RDF145p | C-018 | CATS2D_06_AL | ||||
| Mor16e | 1 | 0.154 | 0.247 | 0.005 | |||
| RDF145p | 1 | 0.058 | 0.586 | ||||
| C-018 | 1 | 0.011 | |||||
| CATS2D_06_AL | 1 | ||||||
|
| |||||||
| RCI | RDF145p | Mor16u | H7s | C-018 | CATS2_04_AL | F03[N-F] | |
| RCI | 1 | 0.110 | 0.007 | 0.157 | 0.010 | 0.115 | 0.008 |
| RDF145p | 1 | 0.155 | 0.558 | 0.058 | 0.585 | 0.045 | |
| Mor16u | 1 | 0.056 | 0.247 | 0.150 | 0.219 | ||
| H7s | 1 | 0.016 | 0.759 * | 0.008 | |||
| C-018 | 1 | 0.091 | 0.766 * | ||||
| CATS2D_04_AL | 1 | 0.092 | |||||
| F03[N-F] | 1 | ||||||
* >cross-correlation Rij = 0.7.
Figure 2Plots representing (a) model linearity, (b) Williams plot and (c) validation using “Y-scrambling”.
Names and definitions of descriptors included in the best one–eight variable models for prediction of TEAC.
| Descriptor Name | Model | Descriptor Definition | Descriptor Type |
|---|---|---|---|
| C-018 | 1-, 2-, 3-, 4-, 5-, 6-, 7- and 8-variable | =CHX | Atom-centred fragments |
| H7s | 2-, 6-, 7- and 8-variable | H autocorrelation of lag 7/weighted by I-state | GETAWAY descriptors |
| CATS2D_06_AL | 3-, 4- and 5-variable | CATS2D Acceptor-Lipophilic at lag 06 | CATS 2D |
| Mor24e | 3-variable | signal 24/weighted by Sanderson electronegativity | 3D-MoRSE descriptors |
| Mor16e | 4-, 5- and 6-variable | signal 16/weighted by Sanderson electronegativity | 3D-MoRSE descriptors |
| RDF145p | 4-, 5-, 6-, 7- and 8-variable | Radial Distribution Function—145/weighted by polarizability | RDF descriptors |
| RCI | 5-, 6-, 7- and 8-variable | ring complexity index | Ring descriptors |
| CATS2D_04_AL | 6-, 7- and 8-variable | CATS2D Acceptor-Lipophilic at lag 04 | CATS 2D |
| Mor16u | 7- and 8-variable | signal 16/unweighted | 3D-MoRSE descriptors |
| F03[N-F] | 7-variable | Frequency of N—F at topological distance 3 | 2D Atom Pairs |
| nR = Ct | 8-variable | number of aliphatic tertiary C(sp2) | Functional group counts |
| F06[N-S] | 8-variable | Frequency of N—S at topological distance 6 | 2D Atom Pairs |